Novel 3-fluoro-4-morpholinoaniline derivatives: Synthesis and assessment of anti-cancer activity in breast cancer cells
作者:Namita A. More、Nitin L. Jadhao、Rohan J. Meshram、Prajakta Tambe、Rajesh A. Salve、Jagjivan K. Sabane、Sanskruti N. Sawant、Virendra Gajbhiye、Jayant M. Gajbhiye
DOI:10.1016/j.molstruc.2021.132127
日期:2022.4
MCF-7 (IC50 1.883 µM) but slightly lower activity against MDA-MB-231 cells (IC50 4.688 µM). The activity of both the compound was also tested on 3T3L-1 Cell line which showed activity similar to clinically approved anti-cancer drug doxorubicin (DOX). The cell death analysis by flow-cytometry confirmed apoptosis mediated cell death in 3T3L-1, MCF-7 and MDA-MB-231 cells when treated with the NAM-5 and NAM-7
杂环吗啉化合物以其抗癌活性而闻名。在这项研究中,新型吗啉及其磺酰胺衍生物被设计和合成为潜在的抗肿瘤药物。新化合物是通过亲核加成反应从胺衍生物中获得的,以 70% 到 90% 的产率提供所需的产物。对所有 31 种化合物进行对接分析。其中,我们代表化合物 NAM-5 和 NAM-7 的对接姿势作为代表。对接分析后,化合物 NAM-5 和 NAM-7 进行了体外测试针对乳腺癌细胞系(MCF-7 和 MDA-MB-231)和健康小鼠胚胎成纤维细胞系(3T3L-1)的抗肿瘤活性。其中,含有磺酰胺基团的化合物 NAM-5 显示出显着的抗增殖活性,对 MCF-7 和 MDA-MB-231 细胞的IC 50 分别为 1.811 µM 和 2.143 µM。另一方面,NAM -7 对 MCF- 7显示出良好的抗增殖活性(IC 50 1.883 µM),但对 MDA-MB-231 细胞的活性略低(IC 504